In the United States, deep<unk>  thrombosis DVT and pulmonary embolism PE<unk> s are more than $9,800 and $14,000 for initial hospitalization respectively, and more than $11,800 and $14,700 for rehospitalization (over half of which occurs within 90 days), respectively.  Several studies have reported that prophylaxis therapy against VTE among surgical patients is<unk>  effective.  According to the Canadian<unk> -effectiveness guidelines in the early 1990s, there is moderate to strong evidence to adopt enoxaparin prophylaxis against DVT after total hip replacement.
Deep vein thrombosis cost-effectiveness of therapy
Deep vein thrombosis landmark trials in treatment
Deep vein thrombosis landmark trials in prevention
Thrombophilia cost-effectiveness of therapy
Deep vein thrombosis future or investigational therapies
Deep vein thrombosis assessment of probability of subsequent VTE and risk scores
Pulmonary embolism assessment of probability of subsequent VTE and risk scores
Deep vein thrombosis treatment approach